Related references
Note: Only part of the references are listed.Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease
Georg Semmler et al.
HEPATOLOGY (2021)
Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes
Mathias Jachs et al.
GUT (2021)
Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers A Tailored Approach
Mathias Jachs et al.
CLINICS IN LIVER DISEASE (2021)
Prevention of First Decompensation in Advanced Chronic Liver Disease
Mattias Mandorfer et al.
CLINICS IN LIVER DISEASE (2021)
Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis
Laura Turco et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy
Mattias Mandorfer et al.
HEPATOLOGY (2020)
The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease
Bernhard Scheiner et al.
LIVER INTERNATIONAL (2020)
Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis
Michael Praktiknjo et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2020)
Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis
Edilmar Alvarado-Tapias et al.
JOURNAL OF HEPATOLOGY (2020)
Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites
Luis Tellez et al.
JOURNAL OF HEPATOLOGY (2020)
Spleen stiffness measurement for assessing the response to beta-blockers therapy for high-risk esophageal varices patients
Giovanni Marasco et al.
HEPATOLOGY INTERNATIONAL (2020)
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
Jonel Trebicka et al.
JOURNAL OF HEPATOLOGY (2020)
Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review
Mattias Mandorfer et al.
SEMINARS IN LIVER DISEASE (2020)
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial
Candid Villanueva et al.
LANCET (2019)
Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis
Tammo L. Tergast et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial
Manoj Kumar et al.
HEPATOLOGY INTERNATIONAL (2019)
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices
Hwi Young Kim et al.
JOURNAL OF HEPATOLOGY (2019)
Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding
N. Pfisterer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity
M. Mandorfer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
JOURNAL OF HEPATOLOGY (2018)
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
Paolo Caraceni et al.
LANCET (2018)
Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis
Paula Gimenez et al.
LIVER INTERNATIONAL (2018)
Stratifying Risk in the Prevention of Recurrent Variceal Hemorrhage: Results of an Individual Patient Meta-Analysis
Agustin Albillos et al.
HEPATOLOGY (2017)
Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis
Roberto Carnevale et al.
JOURNAL OF HEPATOLOGY (2017)
Beta adrenergic blockade and decompensated cirrhosis
Thomas Reiberger et al.
JOURNAL OF HEPATOLOGY (2017)
Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis
Juan G. Abraldes et al.
GASTROENTEROLOGY (2016)
Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure
Rajeshwar P. Mookerjee et al.
JOURNAL OF HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension
Roberto de Franchis
JOURNAL OF HEPATOLOGY (2015)
Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient
Arnulf Ferlitsch et al.
LIVER INTERNATIONAL (2015)
Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis
Philipp A. Reuken et al.
LIVER INTERNATIONAL (2015)
Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis
Mattias Mandorfer et al.
GASTROENTEROLOGY (2014)
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis
Thomas Reiberger et al.
JOURNAL OF HEPATOLOGY (2013)
Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks
Paul Blanche et al.
STATISTICS IN MEDICINE (2013)
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension
Vincenzo La Mura et al.
GUT (2011)
Deleterious Effects of Beta-Blockers on Survival in Patients With Cirrhosis and Refractory Ascites
Thomas Serste et al.
HEPATOLOGY (2010)
beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis
Marco Senzolo et al.
LIVER INTERNATIONAL (2009)
How to prevent varices from bleeding:: Shades of grey -: The case for nonselective β blockers
Ulrich Thalheimer et al.
GASTROENTEROLOGY (2007)